$4,200.00
In Stock
Talz is “This new drug provides patients with an additional treatment option by relieving symptoms such as itching and skin irritation and reducing the discomfort of the disease,” said Julie Beitz, director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.
The active ingredient in Talz is the monoclonal antibody ixekizumab, which binds to the protein interleukin-17A (IL-17A), which provokes inflammation of the skin. Thus, ixekizumab is able to inhibit (suppress) the inflammatory reaction, which plays a key role in the development of plaque psoriasis.
Talz is available as an injection solution. It is intended for patients who are candidates for systemic therapy (treatment with substances that penetrate the blood after oral administration or injection), phototherapy (exposure to the skin with ultraviolet rays) or combination therapy.
The efficacy and safety of the drug were proven in three randomized, placebo-controlled clinical trials involving 3,866 patients with plaque psoriasis who were candidates for systemic therapy or phototherapy. The results showed that Talz was much more effective than placebo in managing the symptoms of the disease: there were virtually no spots left on the patients’ skin.
Since Talz directly affects the immune system, it is released with a special medical guide warning patients about the increased risk of infections, as well as allergic and autoimmune reactions.
Active ingredient: ixekizumab
Prescription medicine
Pack of 3 injections
